| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Dec'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||
Current assets: | ||||||||||||
Cash | ||||||||||||
283 | 546 | 836 | 110 | 134 | 270 | 519 | 543 | 340 | 428 | 453 | 577 | 67 |
Prepaid income taxes | ||||||||||||
20 | 25 | 29 | 60 | - | - | - | - | - | - | - | - | - |
Prepaid expenses | ||||||||||||
84 | 51 | 35 | 38 | 10 | - | 24 | 53 | 50 | 41 | 32 | 29 | 0 |
Total current assets | ||||||||||||
387 | 624 | 901 | 208 | 144 | 270 | 543 | 596 | 390 | 470 | 486 | 607 | 67 |
Deferred offering costs | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | 172 |
Cash and marketable securities held in Trust Account | ||||||||||||
11,979 | 11,877 | 50,671 | 50,028 | 66,326 | 118,165 | 117,677 | 117,358 | 116,916 | 116,588 | 116,539 | 116,205 | 0 |
Total Assets | ||||||||||||
12,367 | 12,501 | 51,572 | 50,237 | 66,471 | 118,436 | 118,220 | 117,954 | 117,307 | 117,058 | 117,025 | 116,813 | 240 |
Liabilities and Stockholders' Equity | ||||||||||||
Current liabilities: | ||||||||||||
Accounts payable and accrued expenses | ||||||||||||
347 | 268 | 86 | 59 | 105 | 94 | 64 | 49 | 56 | 24 | 83 | 105 | 78 |
Franchise and income taxes payable | ||||||||||||
- | - | - | - | 134 | 82 | 63 | 178 | 50 | 88 | - | - | - |
Convertible promissory note - related party | ||||||||||||
371 | 366 | 412 | 322 | 937 | - | - | - | - | - | - | - | - |
Promissory note - CannBioRx | ||||||||||||
- | - | 942 | 400 | - | - | - | - | - | - | - | - | - |
Promissory note - Tyche Capital LLC | ||||||||||||
- | - | 650 | 650 | - | - | - | - | - | - | 0 | 0 | 140 |
Income taxes payable | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 106 | - | - |
Due to related party | ||||||||||||
795 | 795 | 696 | - | - | 369 | 538 | 491 | 156 | 95 | 49 | 7 | 0 |
Advances due - 180 | ||||||||||||
1,699 | 1,699 | - | - | - | - | - | - | - | - | - | - | - |
Total current liabilities | ||||||||||||
3,213 | 3,129 | 2,788 | 1,431 | 1,178 | 546 | 666 | 719 | 262 | 208 | 239 | 112 | 218 |
Deferred underwriting fees | ||||||||||||
4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 0 |
Total Liabilities | ||||||||||||
7,238 | 7,154 | 6,813 | 5,456 | 5,203 | 4,571 | 4,691 | 4,744 | 4,287 | 4,233 | 4,264 | 4,137 | 218 |
Commitments | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
Common stock subject to possible redemption, $0.0001 par value; 12,489 and 33,618 shares as of March 31, 2020 and December 31, 2019, respectively (at approximately $10.39 and $10.33 per share) | ||||||||||||
129 | 347 | 39,759 | 39,780 | 56,268 | 108,865 | 108,529 | 108,209 | 108,019 | 107,825 | 107,761 | 107,675 | 0 |
Stockholders' Equity: | ||||||||||||
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding as of March 31, 2020 and December 31, 2019 | ||||||||||||
- | - | - | - | - | - | 0 | 0 | 0 | - | 0 | 0 | 0 |
Common stock, $0.0001 par value; 35,000,000 shares authorized; 4,479,278 and 4,458,149 shares issued and outstanding (excluding 12,489 and 33,618 shares subject to possible redemption, respectively) as of March 31, 2020 and December 31, 2019, respectively | ||||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Additional paid-in capital | ||||||||||||
4,147 | 3,929 | 3,639 | 3,617 | 3,606 | 3,838 | 4,174 | 4,494 | 4,684 | 4,878 | 4,942 | 5,028 | 24 |
Retained earnings | ||||||||||||
852 | 1,069 | 1,360 | 1,381 | 1,392 | 1,161 | 824 | 505 | 315 | 120 | 57 | -29 | -3 |
Total Stockholders' Equity | ||||||||||||
5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 21 |
Total Liabilities and Stockholders' Equity | ||||||||||||
12,367 | 12,501 | 51,572 | 50,237 | 66,471 | 118,436 | 118,220 | 117,954 | 117,307 | 117,058 | 117,025 | 116,813 | 240 |